Psychometric evaluation of an electronic Asthma Symptom Diary for young children.
Electronic pediatric Asthma symptom diary
Patient-reported outcomes
Psychometric evaluation
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
received:
15
05
2023
accepted:
18
10
2023
medline:
2
11
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Patient-reported outcome measures that facilitate self-report by children are needed to reduce the bias of proxy report. We previously developed an electronic Pediatric Asthma Symptom Diary (ePASD) to assess the severity of daily asthma symptoms and proximal impacts in children aged 6-11 years with mild to severe asthma. The ePASD, administered via a digital application with visuals, sounds, and text, is uniquely designed to minimize the importance of reading skills on children's ability to self-report accurately. Here, we describe the ePASD's psychometric properties. Ninety-one children aged 6-11 years with mild to severe asthma and their caregivers participated in 2 study visits, which consisted of training on the provisioned device and completing asthma-specific clinical outcome assessment (COA) questionnaires. The children self-completed the ePASD at home twice daily for 8 consecutive days. The scoring of the ePASD was guided by factor analyses, inter-item correlations, and internal consistencies. Reliability, discriminating ability, construct validity, and responsiveness were evaluated for ePASD items and candidate scores. All COAs included in the study-the ePASD, Asthma Control Questionnaire (ACQ), Childhood Asthma Control Test, Pediatric Asthma Quality of Life Questionnaire-Standardized (PAQLQ[S]), and global ratings-demonstrated that the children exhibited few asthma-related symptoms and impacts at all timepoints, and consequently, showed little change over time. Internal consistencies (all Cronbach's alphas ≥ 0.52) and test-retest reliabilities (all intraclass correlation coefficients ≥ 0.60) were largely satisfactory. Patterns of convergent and divergent correlations supported the construct validity of ePASD scores. The ePASD symptom scores correlated moderately to strongly with PAQLQ(S) Symptom scores (all correlations ≥ - 0.46) and with ACQ scores (all correlations ≥ 0.42), as predicted. Evidence of the discriminating ability of ePASD items and composite scores was demonstrated by known-groups analyses. The ePASD is a reliable and valid measure of asthma symptoms and proximal impacts in children aged 6-11 years with mild, moderate, or severe asthma. These results lay the psychometric groundwork for use of the ePASD in future clinical trials for the management of pediatric asthma. An ongoing pediatric asthma treatment trial is anticipated to provide evidence of the ePASD's responsiveness to change.
Sections du résumé
BACKGROUND
BACKGROUND
Patient-reported outcome measures that facilitate self-report by children are needed to reduce the bias of proxy report. We previously developed an electronic Pediatric Asthma Symptom Diary (ePASD) to assess the severity of daily asthma symptoms and proximal impacts in children aged 6-11 years with mild to severe asthma. The ePASD, administered via a digital application with visuals, sounds, and text, is uniquely designed to minimize the importance of reading skills on children's ability to self-report accurately. Here, we describe the ePASD's psychometric properties.
METHODS
METHODS
Ninety-one children aged 6-11 years with mild to severe asthma and their caregivers participated in 2 study visits, which consisted of training on the provisioned device and completing asthma-specific clinical outcome assessment (COA) questionnaires. The children self-completed the ePASD at home twice daily for 8 consecutive days. The scoring of the ePASD was guided by factor analyses, inter-item correlations, and internal consistencies. Reliability, discriminating ability, construct validity, and responsiveness were evaluated for ePASD items and candidate scores.
RESULTS
RESULTS
All COAs included in the study-the ePASD, Asthma Control Questionnaire (ACQ), Childhood Asthma Control Test, Pediatric Asthma Quality of Life Questionnaire-Standardized (PAQLQ[S]), and global ratings-demonstrated that the children exhibited few asthma-related symptoms and impacts at all timepoints, and consequently, showed little change over time. Internal consistencies (all Cronbach's alphas ≥ 0.52) and test-retest reliabilities (all intraclass correlation coefficients ≥ 0.60) were largely satisfactory. Patterns of convergent and divergent correlations supported the construct validity of ePASD scores. The ePASD symptom scores correlated moderately to strongly with PAQLQ(S) Symptom scores (all correlations ≥ - 0.46) and with ACQ scores (all correlations ≥ 0.42), as predicted. Evidence of the discriminating ability of ePASD items and composite scores was demonstrated by known-groups analyses.
CONCLUSIONS
CONCLUSIONS
The ePASD is a reliable and valid measure of asthma symptoms and proximal impacts in children aged 6-11 years with mild, moderate, or severe asthma. These results lay the psychometric groundwork for use of the ePASD in future clinical trials for the management of pediatric asthma. An ongoing pediatric asthma treatment trial is anticipated to provide evidence of the ePASD's responsiveness to change.
Identifiants
pubmed: 37902847
doi: 10.1186/s41687-023-00647-y
pii: 10.1186/s41687-023-00647-y
pmc: PMC10616038
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105Subventions
Organisme : Novartis Pharma AG
ID : Not applicable
Informations de copyright
© 2023. The Author(s).
Références
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741507
Qual Life Res. 2019 Apr;28(4):1029-1033
pubmed: 30547346
Multivariate Behav Res. 2009 Mar-Apr;44(2):147-81
pubmed: 26754265
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Int J Tuberc Lung Dis. 2009 Mar;13(3):400-6
pubmed: 19275804
MMWR Surveill Summ. 2021 Sep 17;70(5):1-32
pubmed: 34529643
Pediatr Pulmonol. 2012 Apr;47(4):346-57
pubmed: 22028276
Eur Respir J. 2010 Dec;36(6):1410-6
pubmed: 20530041
J Patient Rep Outcomes. 2022 Mar 20;6(1):25
pubmed: 35306621
Rev Environ Health. 2019 Sep 25;34(3):275-281
pubmed: 31216266
Eur Respir J. 1999 Oct;14(4):902-7
pubmed: 10573240
Pediatr Allergy Immunol. 2011 Feb;22(1 Pt 1):31-5
pubmed: 21261742
Qual Life Res. 1996 Feb;5(1):35-46
pubmed: 8901365
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
J Allergy Clin Immunol. 2007 Apr;119(4):817-25
pubmed: 17353040
Value Health. 2013 Jun;16(4):461-79
pubmed: 23796280
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683